Tag: Biotechnology
-
iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting
STONY BROOK, N.Y. — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to…
-
Hans van der Sluijs Joins BioTork as Chief Development Officer
GAINESVILLE, Fla. — BioTork, the leading evolution biotechnology company, today announced that biotech executive Hans van der Sluijs has joined the company as Chief Development Officer. Hans brings over 20 years of international business leadership experience, with a focus on business development, management, and building strategic alliances/partnerships.
-
Fifteen Neurotechnology Startups to Present at the 2019 Neurotech Leaders Forum in San Francisco
SAN FRANCISCO, Calif. — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that 15 promising neurotechnology startups and early-stage firms will present at the 2019 Neurotech Leaders Forum in San Francisco, November 4-5. The 19th annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting…
-
Brandon Stem Cell Clinic Offers Life-changing Treatment Options
TAMPA, Fla. — Brandon Stem Cell Clinic (BSCC) recognizes that osteoarthritis is one of the most common joint conditions, affecting nearly 630 million people worldwide. It is commonly associated with aging but is also frequently seen in cases of overuse of joints. The growing number of cases alone prove a need for innovative and effective…
-
New Market Research Report on Bioelectronic Medicine Forecasts $16.6B Market
SAN FRANCISCO, Calif. — A newly published market research report from Neurotech Reports, the leading market intelligence firm in the neurotechnology industry, forecasts that the worldwide market for bioelectronic medicine and related technologies will reach $16.6 billion by 2025.
-
The C Diff Foundation Has Declared an Urgent Need to Raise Clostridium difficile Infection Clinical Trial Awareness Worldwide
TAMPA, Fla. — The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.
-
Sue Siegel to Keynote 2019 Bioelectronic Medicine Forum in NY
NEW YORK, N.Y. — Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announces that Sue Siegel, Chief Innovation Officer at GE and CEO of GE Ventures, will keynote the 2019 Bioelectronic Medicine Forum, which takes place in New York City on April 4, 2019. The second-annual event will be held at the Millennium…
-
Neurotech Reports Announces 2018 Investment and Management Conference for Bioelectronic Medicine
NEW YORK, N.Y. — Neurotech Reports, the publisher of Neurotech Business Report newsletter, today announced the launch of the Bioelectronic Medicine Forum, the first investment and management conference for the bioelectronic medicine industry. The inaugural event will take place on March 22, 2018 at the Millennium Broadway Times Square in New York, N.Y.
-
Iron Dust from Brakes and Worldwide Magnesium Deficiencies are Contributing to Hypertension
KESWICK, Va. — With 25 years of research involving primarily the cardiovascular complications of spaceflight and more recently of the moon walkers, particularly Neil Armstrong on his historic mission and James Irwin (Apollo 15), extraordinary findings were discovered. Both had vascular complications, triggered by inhalation of deadly iron-laden dust. Author Dr. William J. Rowe has…
-
ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection
SAN DIEGO, Calif. — ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus’s growing HTS screening collection. This collaboration, which utilized Arcus’s medicinal chemistry knowledge and ChemDiv’s computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures…